Editorial: Pfizer plan to market torcetrapib only with Lipitor sets bad precedent

03/15/2005 | NYTimes.com

Pfizer's plan to market its complementary statin drug only in combination with its Lipitor, denying alternatives for patients who might need them, is "a terrible precedent" for the drug industry, The New York Times editorial says. Torcetrapib is still in trial, but by tying it to Lipitor, the company will be able to extend the Lipitor patent and, in combination, create a blockbuster bigger than Lipitor.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC